Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy
Approval No. 2270 (2025)
Phase 1 small_molecule active
Quick answer
Investigator-Selected Standard PD-1/PD-L1 Inhibitor-Based Therapy for Solid Tumors is a Phase 1 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Solid Tumors
- Phase
- Phase 1
- Modality
- small_molecule
- Status
- active